Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM - nejm.org
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM nejm.org
- Servier Treatment Breakthrough Cited for an Intractable Brain Cancer - WSJ The Wall Street Journal
- Vorasidenib Treatment Shows 'Striking' Results in Low-Grade Glioma Targeted Oncology
- Vorasidenib Is Potential First Targeted Therapy for Low-Grade Glioma OncLive
- Oral Drug for Brain Tumor Could Change Treatment Landscape Medscape
- View Full Coverage on Google News